^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
XZP-5809
i
Other names: XZP-5809, XZP-5809-TT1
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Sihuan Pharmaceutical
Drug class:
EGFR inhibitor
Related drugs:
1year
XZP-5809-TT1 Tablets in Patients With T790M Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer (clinicaltrials.gov)
P1/2, N=21, Terminated, Sihuan Pharmaceutical Holdings Group Ltd. | N=90 --> 21 | Trial completion date: Sep 2022 --> Apr 2022 | Recruiting --> Terminated; Strategic considerations
Enrollment change • Trial completion date • Trial termination • Metastases
|
EGFR mutation • EGFR L858R • EGFR T790M
|
XZP-5809
Share via
